|
Prognosticators vs limits
I'd like to get a better understanding of the logic (if there is any) for barring those with early stage bc who are outside of the time limits set for being eligible to benefit from Herceptin. The scientific assessment of risk at the time of the clinical trial set 1 cm or larger plus factors such as high-grade and HER2 positive as being dangerous enough to need the strongest chemotherapy (Adriamycin) plus radiation, plus if HR+, hormonal treatment as well. At the same time, the scientific assessment of risk in terms of being eligible for the clinical trial as being 2 cm. Can anyone explain the scientific basis for this difference?
|
Threaded Mode